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What’s already known about this topic? 
· There is a need for long-term data on the safety of systemic immunomodulating 
therapies in patients with atopic eczema. 
· Regulatory bodies, such as the European Medicines Agency, increasingly stipulate the 
collection of such data as part of the licensing agreement for new treatments to assess 
the new agent’s long-term safety profile against established therapies. 
· Large numbers of patients with a long duration of follow-up are necessary in order to 
detect rare events like malignancies. 
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· The TREAT Registry Taskforce offers a platform to conduct such research with a 
network of multiple national atopic eczema research registries. 
· We present a protocol for an investigator-initiated multicenter safety study comparing 
dupilumab with other systemic immunomodulating therapies in adults and 
subsequently adolescents and children with moderate-to-severe atopic eczema. 
· This protocol can be used as a framework for similar studies for other novel systemic 




Background: A long-term prospective observational safety study is essential to fully 
characterize the safety profile of systemic immunomodulating therapies for patients with 
atopic eczema. The TREatment of ATopic eczema (TREAT) Registry Taskforce offers a 
large platform to conduct such research using national registries that collect the same data 
using a predefined core dataset. 
 
Objectives: We present a protocol for a safety study comparing dupilumab with other 
systemic immunomodulating therapies in children and adults with moderate-to-severe atopic 
eczema to assess the long-term safety risk of these therapies in a routine clinical care setting. 
 
Methods: We describe a registry-embedded international observational prospective cohort 
study. Adult and paediatric patients who start treatment with dupilumab or anothersystemic 
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the incidence of malignancies (excluding non-melanoma skin cancer) compared between the 
treatment groups. Secondary endpoints include other serious adverse events and adverse 
events of special interest, such as eye disorders and eosinophilia.  
 
Conclusions: This protocol delineates a safety study for dupilumab in adult and paediatric 
patients with atopic eczema, using a standardized methodological approach across several 
national registries. The protocol could also be used for other novel systemic 
immunomodulating therapies and could provide licensing and reimbursement authorities, 





In a substantial number of patients with atopic eczema systemic immunomodulating therapies 
are required because the disease is not sufficiently controlled with topical therapies.1 
Ciclosporin  was until recently the only systemic treatment approved in Europe and only in 
adults with severe disease.2 The frequency and duration of the use of ciclosporin is limited 
due to the risk of renal toxicity and hypertension. In addition, neurological symptoms, fatigue 
or gastrointestinal symptoms, next to treatment failure are reasons for patients to discontinue 
their treatment.3 Ciclosporin has many potential contra-indications and drug interactions. 
Alternative systemic immunomodulating therapies are used off-label and include 
methotrexate, mycophenolic acid, mycophenolate mofetil and azathioprine.4 These treatments 
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liver toxicity and teratogenicity.7 Azathioprine and ciclosporin have been associated with an 
increased risk of incident cancer.8-11 However, the relative contribution of the diseases 
themselves and disease-related risk factors are difficult to separate from treatment-related 
factors. 
 
Dupilumab, a monoclonal antibody binding to the alpha subunit of the interleukin-4 receptor 
(IL-4Rα), has recently been approved by both the Food and Drug Administration (FDA) in 
the U.S.A. and European Medicines Agency (EMA) for the treatment of adult patients with 
moderate-to-severe atopic eczema. Regarding short-time safety, clinical trials on dupilumab 
have shown no significant difference in the proportion of patients with at least one adverse 
event in comparison to placebo, nor were there serious adverse events related to dupilumab. 
Injection-site reactions and conjunctivitis were the most commonly reported adverse 
events.12, 13 Eosinophilia has been reported in trials investigating dupilumab treatment in 
patients with asthma, with symptomatic hypereosinophilia being observed in rare cases.14, 15 
In atopic eczema studies asymptomatic eosinophilia has been observed.12, 16 In addition, 
conflicting evidence exists about the role of IL-4 in tumor promotion.17, 18 The long-term 
safety of dupilumab has not yet been investigated. 
 
In order to fully characterize the safety profile of the long-term use of dupilumab and mostly 
off-label systemic treatments among patients with atopic eczema, a long-term, prospective, 
observational safety study is essential and often stipulated by the licensing body, such as the 
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The TREatment of ATopic eczema (TREAT) Registry Taskforce is an international network 
of research registries which collect observational data of adult and paediatric patients with 
atopic eczema in a harmonized fashion.19 Consensus was reached on a core dataset based on 
an international Delphi exercise among over 400 stakeholders from over 20 countries.20, 21 
Recently, recommendations for measurement instruments have been added to this core 
dataset.22 Currently, TREAT registries are being established in different European countries 
and in North America. Countries participating in the TREAT registry initiative are the U.K., 
Ireland, the U.S.A., Germany, the Netherlands, Denmark, Sweden, France, Italy, Spain and 
Portugal. 
 
Data collected in a harmonized and standardized fashion across the TREAT registries can be 
used for the purpose of conducting a long-term safety study and here we present a study 
protocol for such an approach. The main objective of this study is to characterize the long-
term safety profile of dupilumab compared to other systemic immunomodulating therapies 
for the treatment of atopic eczema in a routine clinical care setting. 
 
Patients and methods 
Study design 
A registry-embedded long-term international prospective cohort study is conducted, aiming 
to recruit adult and paediatric patients with atopic eczema who start treatment with 
dupilumab and to compare the adverse event rates in this cohort with a cohort starting 
treatment with other systemic immunomodulating therapy (e.g. ciclosporin, methotrexate, 
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observational nature where interventions are initiated by the treating physician and not 
determined by the study. Coordinating centres of this study are the sites that coordinate the 
atopic eczema registries of the TREAT Registry Taskforce, each with a network of recruiting 
sites. Our European initiative has been registered as a research network with the European 
Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCEPP).23 
 
Patient population 
The study population consists of patients with a physician diagnosis of atopic eczema, who 
are starting on or switching to a systemic immunomodulating treatment for their atopic 
eczema that they have not received before. We aim to include as many dupilumab-treated 
patients as those treated with other systemic immunomodulating therapies as 
contemporaneous comparator. Participants need to be willing to comply with all study 
requirements and provide consent to participate in long-term follow-up for the collection of 
observational data during their visits, including adverse event recording and disease severity 
assessments. Written informed consent is obtained from each patient before participation. 
 
Patients will not be allowed to be enrolled in the study if they are concurrently participating 
in an interventional study of systemic therapy for atopic eczema. The study participants can 
be enrolled in clinical trials prospectively. We will record if participants are participating in 
an investigational trial and include this as a variable in our analysis. If possible, follow-up 
visits for this safety study will be continued during the investigational trial. Participants can 
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Study schedule  
During the observation period, participants will be assessed on at least a 6 monthly basis 
while on therapy and at least annually off systemic immunomodulating treatment to collect 
data on adverse events and reasons for potential changes in therapy. A +/-2 months visit 
window will be applied. The study aims to monitor patients for as long as possible, aiming 




- Incidence rate ratios of cancer (any pathology-confirmed malignant tumour or cancer 
excluding non-melanoma skin cancer (NMSC)) within the follow-up period 
comparing the group receiving dupilumab and the group receiving other systemic 
immunomodulating treatments. 
Secondary endpoints: 
- Incidence rate ratios of serious adverse events (any untoward medical occurrence that 
results in death, is life-threatening, requires in-patient hospitalization or prolongation 
of existing hospitalization, results in persistent or significant disability or incapacity, 
or consists of a congenital anomaly or birth defect, including serious infections (e.g 
pneumonia, septicaemia, bone, joint and opportunistic infections)24) within the 
follow-up period comparing the groups. 
- Incidence rate ratios of other adverse events of special interest in the groups: 
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conjunctivitis,blepharitis, and other eye disorders as diagnosed by an ophthalmologist 
if appropriate), skin cancer (including both melanoma and NMSC), cardiac disorders 
(e.g. myocardial infarction), central nervous system disorders (e.g. demyelination, 
peripheral neuropathy, seizures), and haematological disorders (e.g. aplastic anaemia, 
pancytopaenia). 
- Discontinuation rate of dupilumab due to adverse events, compared to the 
discontinuation of the other systemic treatments. 
.  
Sample size 
The definite power calculation will be based on the anticipated frequency of the outcomes. 
Under the assumption of 80% power and 5% alpha error (2-sided), a hazard ratio (HR) of 2 
and 1:1 ratio of patients exposed vs. non-exposed to dupilumab (primary exposure) requires 
66 events in the study.25 Due to non-random allocation of patients between the groups a R2 
(r-squared) of exposure to dupilumab explained by other covariates = 0.2 is considered. 
Assuming an annual incidence rate of any cancer (excluding NMSC) of 33 per 10,000 
patients,26 this results in 82 events.27 There would be less power to detect the rare cancer 
specific subtypes, such as lymphoma and melanoma, unless the risk difference is very large. 
Our assumed HR for this power calculation is in line with the standard EMA requirements for 
a post-marketing safety study focused on cancer. A safety study should be large enough to 
detect a two folded increases risk for cancer (without NMSC). If the risk is higher than a HR 
of 2 the desired 82 cancer events would happen earlier in time and if the risk is smaller than a 
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Furthermore, a dropout rate of 20% including those with only limited exposition to 
dupilumab (exposure to dupilumab < 4 weeks) or other possible future biologicals is 
assumed. To achieve these 82 events, we are dependent on the number of recruited patients, 
the speed of recruiting and the time the patients are under observation in the registry. Table 1 
gives an overview about possible scenarios if recruitment is uniformly distributed over the 
recruitment period. By recruiting 1000 patients (N_y) per year over three years (Y_rec) the 
desired number of 82 events will appear in the 9th year of the study. By recruiting 800 
patients per year over four years the desired number of 82 events will also appear in the 9th 
year of the study but require overall 3200 instead of 3000 patients to be included in the study. 
Exposure to dupilumab and other systemic immunomodulating treatments for atopic eczema 
will vary over time. It is expected that many patients will be exposed to more than one 
systemic immunomodulating agent within the study period. Differences in previous exposure 
to systemic immunomodulating atopic eczema treatments also have to be considered as 
potential confounders in the analysis. Additionally, a certain lag time has to be assumed 
between relevant exposures and detection of incident cancer. Long latency adverse events, 
like cancer, will be linked to a drug if patients were ever exposed to the drug. Short latency 
adverse events, like eye disorders, will be linked to a drug if they took place while the patient 
was using the drug or within 90 days after the end of exposure.  
 
Statistical analysis 
The data from each participating registry will be analysed separately at first. A descriptive 
analysis of baseline patient characteristics and medical history will be presented. Categorical 
variables will be summarized by number and percentage in each category. Missing data will 
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incidence rates of malignancies, including 95% two-sided confidence intervals, will be 
estimated for the treatment groups. 
 
The data from each registry will then be pooled and a comparative analysis will be performed 
on the pooled data to estimate if there is a difference in the incidence rates for malignancies 
or serious infections and the other adverse events of interest between the treatment groups. In 
the primary confirmatory analysis exposure to dupilumab will be handled as a binary 
variable, i.e. patients are classified as exposed if they received dupilumab at least once within 
the study period; otherwise as non-exposed. The log-rank test will be used followed by cox 
proportional hazard models. Potential confounders and effect modifiers (age, sex, previous 
treatments (including previous phototherapy), malignancy history, smoking, family history, 
co-treatments, socioeconomic position, country etc.) will be tested and included in the cox 
model if they improve the model fit according to the Bayesian information criterion. Primary 
population for analysis will be all patients up to the point when 82 cancer events appear. The 
analyses will take into account switching from one drug to another as well as medical 
(therapeutic) history, such that the person-years of follow-up switch to the new drug when 
this is initiated. 
 
Sensitivity analyses will: 
- Consider history of malignancy 
- Include analyses stratified by cancer type (including NMSC) 
- Consider lag time of exposure and cancer incidence of 12 months 
- Explore a potential dose-response effect of cumulative dupilumab exposure 
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Data collection 
Each country will use a purpose-built online data entry platform to prospectively collect the 
study data. All data will be pooled across countries for the final analyses. The pseudonymised 
data of each national registry will be hosted on secure servers. All data will be additionally 
stored on a backup server in case of data loss. Only registered local investigators and 
delegated study members will have access to the data entry platform and only to the data of 
their own patients.  
 
Data capture includes a case record form (CRF) based on the TREAT core dataset.21, 22 A 
variety of parameters will be collected during the study visits. Concerning safety, data on the 
predefined adverse events, including severity, seriousness, and relatedness to therapy as part 
of pharmacovigilance will be recorded at each follow-up visit and entered into the CRF. All 
predefined malignancy and other pre-defined adverse event categories will be recorded using 
MedDRA (Medical Dictionary for Regulatory Activities) data dictionary coding. Where 
possible, the use of data from national cancer registries will be explored. In case of loss to 
follow-up, every effort will be made  to collect information on the reason for this, including 
data on a potential (serious) adverse event related to this. 
 
Study governance structure 
The safety study will be governed by a Steering Committee (SC), consisting of the Chair 
(Study Lead Investigator), the Co-Chair (Deputy Lead Investigator) and all country Principal 
Investigators (PI) and Co-PIs. The SC will be responsible for the running and management of 
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In addition, there will be a Data Monitoring Committee (DMC), an independently formed 
committee with responsibility for monitoring the patient safety. The DMC safeguards the 
interests of the patients participating in the study. It is the job of the DMC to monitor the 
comparative data and make recommendations to the SC on whether there are any ethical or 
safety reasons why the study should not be continued. They can also advise on modifications 
to the protocol. Apart from its Chair, the DMC will have at least one statistician and at least 
two clinicians not directly involved in the study, with an interest in pharmacovigilance. 
 
Discussion 
The current evidence to inform clinical management for moderate-to-severe atopic eczema 
stems from a small body of randomized controlled trials.28-33 The psoriasis literature indicates 
that approximately 30% of patients entered into registries would be ineligible for clinical 
trials.34 In addition, procedures differ between trials and routine clinical practice which 
impairs the generalizability of the findings. There is no long-term, comparative and 
observational data on effectiveness and safety of systemic immunomodulating therapies for 
atopic eczema from a large-scale multicenter international cohort study. Several guidelines 
and a systematic review highlight these gaps.35-37 
The overall aim of the described study is to provide data on the long-term safety of 
dupilumab compared with other systemic immunomodulating therapies for the treatment of 
atopic eczema in adults and children. The observational nature of the study, using the 
platform of registries of the TREAT Registry Taskforce, guarantees the collection of data 
from patients in a routine clinical care setting. The described standardized methodological 
approach across registries will allow data pooling, in order to obtain the large number of 
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A limitation of the study is that although the severity of disease requiring dupilumab 
treatment or another novel systemic agent is likely to be closely comparable to that of those 
exposed to another systemic immunomodulating drug intervention , the decision to start 
dupilumab treatment will most frequently be based on access to these novel systemic agents 
and a lack of suitability of or responsiveness to other immunomodulating therapies rather 
than on disease severity. This is likely to result in differences between treatment groups, for 
example in the responsiveness to standard agents, which cannot be quantified other than by 
fully documenting previous systemic treatments for atopic eczema and then adjust for such 
confounders in statistical analysis.  
 
Individuals commencing novel systemic treatments have often received multiple systemic 
therapies in the past. Limiting the study only to new users of such therapies would restrict the 
dupilumab group to patients with contraindications for many other therapies. This approach 
would undermine the scope of evidence from the routine clinical care setting and introduce 
bias.38 Our data will take into account sequential treatment switching decisions that typically 
take place in routine clinical practice and that are almost impossible to study in clinical trials.    
 
The need for long-term safety studies for other therapies will increase, as many other novel 
therapies are currently being assessed in clinical trials. The described study protocol 
primarily concerns a comparison between dupilumab and other systemic therapies. However, 
this protocol can be used as a framework for similar studies for other novel systemic 
immunomodulating therapies across both adult and paediatric populations within the TREAT 
Registry Taskforce. The described study could be adapted to include and collect on any drug 
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also collect similar adverse event data on all other systemic therapies the participants are on. 
This will allow safety comparisons between all other systemic immunomodulating therapies, 
provided that the number of treated patients and power is adequate.  
 
This study will run as an investigator-led project but is open to receive financial support from 
charities, governments as well as pharmaceutical companies, who might want to task the 
study team with the follow-up of patients on their agents. This approach could provide 
pharmaceutical companies post-authorization safety data on their systemic therapies as 
requested by licensing and regulatory bodies.  
 
Next to the countries that have already started, several other countries have shown their 
interest in joining in the TREAT Registry Taskforce (treat-registry-taskforce.org) and 
establishing a TREAT registry. This offers opportunities for expansion of this and similar 
studies for other systemic therapies in the future. 
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TABLES AND FIGURES  
Table 1: Distribution of follow-up time in years for different recruitment scenarios to 
achieve estimated event numbers at the end of the year, assuming recruitment is 
uniformly distributed over the recruitment period with 20% dropout and a background 
incidence of 33 per 10.000 person years. 
 
N_y Y_rec 3y 4y 5y 6y 7y 8y 9y 10y 11y 12y 13y 14y 
600 3 11 18 25 32 39 45 52 59 66 73 79 86 
800 3 14 24 33 42 51 61 70 79 88 97 106 115 
1000 3 18 29 41 53 64 76 87 99 110 121 132 143 
600 4 11 19 28 38 47 56 65 74 83 92 101 110 
800 4 14 25 38 50 62 75 87 99 111 123 135 147 
1000 4 18 31 47 63 78 93 109 124 139 154 169 184 
600 5 11 19 29 41 53 64 76 87 99 110 121 132 
800 5 14 25 39 55 70 86 101 116 131 147 162 176 
1000 5 18 31 49 69 88 107 126 145 164 183 202 221 
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